Nilotinib targets the BCR-ABL protein, which is a fusion protein resulting from a genetic abnormality. This fusion protein has abnormal tyrosine kinase activity, driving the proliferation of leukemic cells. By inhibiting this protein, nilotinib helps to reduce the proliferation of cancerous cells and induce apoptosis, or programmed cell death.
